Complement C5 inhibitor

This page covers all Complement C5 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Complement protein C5, C5, C5 (Complement protein 5).

Targets

Complement protein C5 · C5 · C5 (Complement protein 5) · Complement C5

Marketed (1)

• Eculizumab (Soliris®) · Massachusetts General Hospital · Immunology
  Eculizumab is a monoclonal antibody that blocks complement protein C5, preventing the formation of the membrane attack complex and reducing complement-mediated cell destruction.

Phase 3 pipeline (4)

• Spacing of Eculizumab infusions · University Hospital, Tours · Immunology
  This study investigates optimal dosing intervals for eculizumab, a complement C5 inhibitor, to maintain therapeutic efficacy while potentially reducing treatment burden.
• C5 Inhibitor · Alexion Pharmaceuticals, Inc. · Immunology
  A C5 complement inhibitor blocks the activation of the C5 component of the complement cascade, preventing formation of the membrane attack complex and reducing inflammatory cell activation.
• Eculizumab Injection · Wuhan Createrna Science and Technology Co., Ltd · Immunology
  Eculizumab is a monoclonal antibody that inhibits the complement protein C5, blocking the formation of the membrane attack complex and reducing complement-mediated cell destruction.
• BOL-303259-X · Bausch & Lomb Incorporated · Ophthalmology
  BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye.